Member Info for inanaco

https://www.researchgate.net/publication/330858936_Abstract_B122_Development_of_a_new_immunotherapy_treatment_for_glioblastoma_multiforme

Glioblastoma multiforme (GBM) is the most frequently occurring primary brain tumor; it is a debilitating disease that is associated with poor prognosis, short median patient survival and a limited response to current therapies. As a result, there is a dire need for novel therapeutic interventions that are curative, or at the very least extend patient survival. Immunotherapy is an attractive option for the treatment of GBM due to its high specificity and minimal systemic toxicity. Peripherally activated immune cells have been shown to efficiently penetrate the brain parenchyma and access intracranial tumors, overcoming the blood-brain barrier, which hinders many molecularly targeted therapies. Two antigens, TRP-2 and WT-1, were found to be significantly expressed in GBM tissue sections while being absent from the normal brain. Peptide sequences known to be immunogenic were chosen from both TRP-2 and WT-1 antigens. The DNA sequences corresponding to these peptide sequences were then inserted into the complementarity determining regions of a DNA plasmid encoding an antibody known as ImmunoBody®; this vaccine has been shown to generate a higher avidity response than both peptide and peptide-pulsed dendritic cell vaccinations. As a result of the highly promising preclinical results shown, the ImmunoBody® vaccination is currently being studied in a phase I/II clinical trial for melanoma. As a result the ImmunoBody® DNA vaccine has been selected as our method of vaccination. Syngeneic C57BL/6 mice and humanized C57BL/6 HHDII/DR1 mice were used to assess the TRP-2 and WT-1 directed ImmunoBody® vaccines. Mice were vaccinated biolistically with the ImmmunoBody® plasmid coated onto gold particles using a gene gun. An initial priming dose was given on day 0 followed by a boost on days 7 and 14. Mice were vaccinated with either a TRP-2-ImmunoBody®, a WT-1-ImmunoBody® or a combination of the two. The immune response generated was determined by ex vivo IFN-? ELISpot using splenocytes derived from the spleen of immunized animals. Results from these dual vaccination experiments reveal that it is possible to use both of these vaccines in tandem without losing the specificity towards each vaccine-containing peptide. High level of peptide-specific IFN-?-releasing cells were detected directly ex vivo and the ability of these IFN-?-releasing cells to recognize targeT-cells that naturally express the WT-1 and TRP-2 antigens is being investigated. The efficacy of TRP-2-ImmunoBody® with or without PD-1 at treating syngeneic orthotopic GL-261Luc2 tumors implanted in
C57BL/6 mice is also currently being assessed. The combination of the two vaccines will also be assessed in the humanized HHDII/DR1 mice using a humanized B16 cell line that has had murine Beta-2m knocked out and HHDII and HLA-DR1 knocked in. Anti-PD-1 checkpoint blocka

bit more here

https://www.ejcancer.com/article/S0959-8049(18)30058-3/abstract

It is ... good find, agree .......... sorry i was getting my head around the science

From scancells point of view ... looks like another Como trial ..

using Immunobody

with CAF09 eliciting strong immune responses in both models, and ImmunoBody® eliciting potent immune responses in C57Bl/6 mice. Indeed, a higher proportion of CD8+ T-cells were able to release IFN? and TNFa, to proliferate (Ki67 expression) and to degranulate (CD107a and Granzyme B expression) after short incubation with MHC class-I peptide.

this part .......

""The PAP-114-128 epitope ""

relates to this

This sequence has now been granted patent in Europe and in the US. Preclinical works are ongoing to gather the necessary data for a phase-0/I clinical trial for the treatment of hormone resistant prostate cancer.

the Pap is the immune response Crumbs not the vaccine ....

""Prostatic acid phosphatase (PAP) is a prostate-specific protein""

CAF09 and ImmunoBody® were superior to CpG in inducing PAP-specific immune responses,

many rivers are out ... but not in kent ...

although see 7 might have something to do with it ...

Dr surgery only for the 23 version

Boots pharmacy will only inject the 13 version privately ..

and i suggest those concerned should get that jab asap ... probably have to go Private if you don't meet NHS criteria probably about £70

C7
check which vaccine you have received ..
it was probably Pfizer 13 variant which is what they gave me .. just checked

but you should get the Merck version which is 23 variants as an upgrade ..

easy way round that ... get yourself arrested
You are then the states responsibility ..

trust what is Known ...

The Pneumovax 23 covers twenty three different variants of the pneumococcal bacteria. In healthy adults, revaccination is not indicated (necessary). Patients with underlying chronic disease should probably be revaccinated every 5 years.

just spotted that 5 years

mmmmmmmmmmm worth a booster

To take a view needs evidence really ... not sure how you would come by that

SP gives you no indicator at all .. you can see that by the sp not reacting to avidmab and the FDA .. really we should be back in the twenties now . Maybe tomorrow ... who knows

Ray what do you mean .. are you suggesting an alternative route to trial ?

SCIb2 would take a year to manufacture ...

ATB

toxicity

https://www.mayoclinicproceedings.org/article/S0025-6196(19)30275-7/fulltext

yes immunobody can be used against Virus ... but a Virus rarely needs the potency of immunobody

its also an expensive vaccine because of the extra cost of delivery compared to traditional virus vaccines ...

you could always introduce "extra Damp" mate ...

well we should introduce a new word to wind up some ...

"extra minted"

I agree ... but the value of the Scancell formula is very clear .. and very few can, even those with efficacy like the PD-1 ctl-4 inhibitors and checkpoints can get anywhere near us on

""Off Target Toxicity""

Don't forget every patient that drops out of trials because of toxicity is going to cost you big time in the market. This fantastic "headline" results that have been achieved often disguise what patients are put through ....

as Bermuda highlighted we are now entering "Tri combinations" .... let alone dual combinations ... and as i have pointed out
a Vaccine can still be added .. because if your vaccine induced off target toxicity, you have effectively generated an autoimmune reaction .. self attacks self ....

so if you go back to Wildforces link ... "Risk of off target"

The normal tissue distribution of FG129 was evaluated using two normal human TMAs:
AMSbio, T8234708-5, covering 31 tissues, one normal human individual per tissue, in
duplicate, and US Biomax, FDA999i, 32 types of normal organs from three individuals, single
core per case. On the AMSbio array, FG129 displayed a very restricted binding pattern and
did not bind most normal tissues, including vital tissues such as heart, brain, stomach and
kidney (Table S3 and Figure 2C). Weak to moderate binding of a very small percentage of
cells was seen in gallbladder, ileum, liver, oesophagus, pancreas and thyroid. In contrast the
CA19.9 mAb stained a subset of tissues: oesophagus, liver and pancreas with strong intensity
(Table S3). Additionally, the majority of tissues on the US Biomax array were negative with
low to moderate staining of a small fraction of cells on tonsils (1/3), thymus (2/3); salivary
gland (1/3); oesophagus (3/3); adjacent normal (1/3) and cancer adjacent uterine cervix tissue
(2/3) (Figure S3).

ran out of space .................. efficacy ..

missing the last "y"